Nicotinamide phosphoribosyltransferase (NAMPT), a critical enzyme for the NAD+ salvage pathway is reportedly overexpressed in numerous cancer types including breast cancer and treatment of cancer cells with the NAMPT inhibitor, FK866, is an active area of preclinical testing [36]. The gene discussed is NAMPT; the disease is breast carcinoma.